Analysis of the secretin stimulation for pancreatic juice cytology

Analysis of the secretin stimulation for pancreatic juice cytology - Analysis of the secretin stimulation for pancreatic juice cytology

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018557

Enrollment

250

Registered

2015-08-06

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic diseases

Interventions

Intravenous secretin administration (1.2mcg/body at the time of ERP )

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Aged 20 or more year-old 2) Patients who undergo ERP and pancreatic juice cytology for their pancreatic diseases 3) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients who have a history of severe complications due to ERP 2) Patients who have a history of complications due to secretin 3) Patients who have a history of drug allergy 4) Not written informed consent 5) Patients who the doctor-in-charge figures unsuitable for this study

Design outcomes

Primary

Measure	Time frame
The accuracy of pancreatic juice cytology	—

Countries

Japan

Contacts

Public ContactYoshitaka Gotoh

Graduate School of Medical Sciences, Kyushu University Department of Surgery and Oncology

y-gotoh@surg1.med.kyushu-u.ac.jp092-642-5441

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026